Human GARP (LRRC32) Antibody from BIOLEGEND

Search, find, compare suppliers for anti-Human GARP (LRRC32) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityHuman GARP (LRRC32)
Clone7B11
Host SpeciesMouse
Reactive Specieshuman
IsotypeIgG2b, κ
FormatBrilliant Violet 711™ conjugate
Size25 tests
Concentrationn/a
ApplicationsFlow Cytometry (FC)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionBrilliant Violet 711™ anti-human GARP (LRRC32).

Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs (CD4+, CD25+, FoxP3+ cells) and serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1, an autosomal recessive disease characterized by profound congenital sensorineural deafness, vestibular dysfunction, and progressive visual loss. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

ImmunogenLRRC32-DNA vaccination
Other NamesGarpin, Glycoprotein A repetitions predominant
Gene, Accession #Gene ID: 2615
Catalog #352521
Price$230
Order / More InfoHuman GARP (LRRC32) Antibody from BIOLEGEND
Product Specific Referencesn/a
BIOLEGEND
BIOLEGEND
BIOLEGEND
8999 BioLegend Way
San Diego CA 92121
P: (858) 455-9588
P: 1-877-Bio-Legend (246-5343)
F: (858) 455-9587

customerserv@biolegend.com

http://www.biolegend.com

Profile of BIOLEGEND
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.